A detailed history of Price T Rowe Associates Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,350,880 shares of DAWN stock, worth $36.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,350,880
Previous 2,299,764 2.22%
Holding current value
$36.3 Million
Previous $38 Million 14.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$12.03 - $17.69 $614,925 - $904,242
51,116 Added 2.22%
2,350,880 $32.4 Million
Q1 2024

May 15, 2024

SELL
$13.56 - $17.46 $230,520 - $296,820
-17,000 Reduced 0.73%
2,299,764 $38 Million
Q4 2023

Feb 14, 2024

BUY
$9.68 - $15.37 $84,564 - $134,272
8,736 Added 0.38%
2,316,764 $33.8 Million
Q3 2023

Nov 14, 2023

SELL
$11.22 - $14.86 $19,107 - $25,306
-1,703 Reduced 0.07%
2,308,028 $28.3 Million
Q2 2023

Aug 14, 2023

BUY
$11.74 - $14.47 $7.57 Million - $9.33 Million
644,980 Added 38.74%
2,309,731 $27.6 Million
Q1 2023

May 15, 2023

SELL
$12.75 - $23.41 $6.6 Million - $12.1 Million
-517,827 Reduced 23.73%
1,664,751 $22.3 Million
Q4 2022

Feb 14, 2023

BUY
$18.77 - $22.0 $1.65 Million - $1.93 Million
87,665 Added 4.18%
2,182,578 $47 Million
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $880,674 - $1.42 Million
53,569 Added 2.62%
2,094,913 $42 Million
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $2.61 Million - $8.16 Million
455,603 Added 28.73%
2,041,344 $36.5 Million
Q1 2022

May 16, 2022

BUY
$9.12 - $17.47 $43,438 - $83,209
4,763 Added 0.3%
1,585,741 $15.7 Million
Q4 2021

Feb 14, 2022

BUY
$15.65 - $26.33 $1.17 Million - $1.97 Million
74,652 Added 4.96%
1,580,978 $26.6 Million
Q3 2021

Nov 15, 2021

BUY
$20.0 - $27.92 $18,600 - $25,965
930 Added 0.06%
1,506,326 $34.9 Million
Q2 2021

Aug 16, 2021

BUY
$19.0 - $23.69 $28.6 Million - $35.7 Million
1,505,396 New
1,505,396 $33.4 Million

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.13B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.